
## Eric A Secemsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9029750/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2016, 315, 1735.	3.8	759
2	Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices. JAMA Cardiology, 2019, 4, 332.	3.0	178
3	Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Circulation, 2014, 130, 2295-2301.	1.6	109
4	Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. BMJ: British Medical Journal, 2018, 363, k5094.	2.4	103
5	Contemporary Management and Outcomes of Patients with Massive and Submassive Pulmonary Embolism. American Journal of Medicine, 2018, 131, 1506-1514.e0.	0.6	79
6	Conscious Sedation Versus General Anesthesia for Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2020, 13, 1277-1287.	1.1	73
7	Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals. JACC: Heart Failure, 2015, 3, 591-599.	1.9	65
8	Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry. Circulation, 2021, 143, 2229-2240.	1.6	64
9	Drug-Eluting Stent Implantation and Long-Term Survival Following Peripheral Artery Revascularization. Journal of the American College of Cardiology, 2019, 73, 2636-2638.	1.2	59
10	Editor's Choice – International Variations and Sex Disparities in the Treatment of Peripheral Arterial Occlusive Disease: A Report from VASCUNET and the International Consortium of Vascular Registries. European Journal of Vascular and Endovascular Surgery, 2020, 60, 873-880.	0.8	52
11	Public Reporting in Cardiovascular Medicine. Circulation, 2015, 131, 1518-1527.	1.6	50
12	Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: A systematic review and meta-analysis. Vascular Medicine, 2020, 25, 106-117.	0.8	50
13	Readmissions After Revascularization Procedures for Peripheral Arterial Disease. Annals of Internal Medicine, 2018, 168, 93.	2.0	48
14	Patient Readmission Rates For All Insurance Types After Implementation Of The Hospital Readmissions Reduction Program. Health Affairs, 2019, 38, 585-593.	2.5	44
15	Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease. JACC: Cardiovascular Interventions, 2017, 10, 942-954.	1.1	38
16	Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries. JAMA Internal Medicine, 2021, 181, 1071.	2.6	38
17	Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. Circulation: Heart Failure, 2018, 11, e004312.	1.6	37

Comparison of Short- and Long-Term Cardiac Mortality inÂEarly Versus Late Stent Thrombosis (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf

#	Article	IF	CITATIONS
19	Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association. Circulation, 2021, 144, e70-e91.	1.6	36
20	Changes in Care for Acute Pulmonary Embolism Through A Multidisciplinary Pulmonary Embolism Response Team. American Journal of Medicine, 2020, 133, 1313-1321.e6.	0.6	33
21	High Burden of 30â€Ðay Readmissions After Acute Venous Thromboembolism in the United States. Journal of the American Heart Association, 2018, 7, .	1.6	32
22	Utilization and Outcomes of Thrombolytic Therapy for Acute Pulmonary Embolism. Chest, 2020, 157, 645-653.	0.4	32
23	The impact of skin hyperpigmentation and hyperchromia on quality of life: A cross-sectional study. Journal of the American Academy of Dermatology, 2017, 77, 775-778.	0.6	31
24	Supervised Exercise Therapy for Symptomatic Peripheral Artery Disease Among Medicare Beneficiaries Between 2017 and 2018: Participation Rates and Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007953.	0.9	31
25	Comparison of 30-Day Readmission Rates After Hospitalization for Acute Myocardial Infarction in Men Versus Women. American Journal of Cardiology, 2017, 120, 1070-1076.	0.7	30
26	Use and Effectiveness of Bivalirudin VersusÂUnfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. JACC: Cardiovascular Interventions, 2016, 9, 2376-2386.	1.1	29
27	Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003464.	1.4	28
28	Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. JAMA Cardiology, 2019, 4, 110.	3.0	26
29	Pregnancy-associated arterial dissections: a nationwide cohort study. European Heart Journal, 2020, 41, 4234-4242.	1.0	25
30	Assessing the safety of superficial chemical peels in darker skin: A retrospective study. Journal of the American Academy of Dermatology, 2018, 79, 508-513.e2.	0.6	24
31	Effect of Left Ventricular Dysfunction and Viral Load on Risk ofÂSudden Cardiac Death in Patients With Human ImmunodeficiencyÂVirus. American Journal of Cardiology, 2014, 113, 1260-1265.	0.7	22
32	Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting. JAMA Cardiology, 2017, 2, 478.	3.0	22
33	Examining the Operator Learning Curve for Percutaneous Coronary Intervention of Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2019, 12, e007877.	1.4	22
34	Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2016, 5, .	1.6	21
35	Research Techniques Made Simple: Web-Based SurveyÂResearch in Dermatology: Conduct andÂApplications. Journal of Investigative Dermatology, 2018, 138, 1456-1462.	0.3	21
36	Racial and ethnic disparities in melanoma awareness: A cross-sectional survey. Journal of the American Academy of Dermatology, 2020, 83, 1098-1103.	0.6	21

#	Article	IF	CITATIONS
37	Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Internal Medicine, 2020, 180, 1317.	2.6	21
38	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by <scp>SCAI</scp> and <scp>NKF</scp> . Catheterization and Cardiovascular Interventions, 2021, 98, 416-426.	0.7	21
39	Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006589.	0.9	20
40	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation, 2022, 145, 97-106.	1.6	20
41	Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 651-658.	1.1	19
42	Update on paclitaxel for femoral-popliteal occlusive disease in the 15Âmonths following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel. Journal of Vascular Surgery, 2021, 73, 311-322.	0.6	19
43	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral ArteryÂRevascularization. Journal of the American College of Cardiology, 2021, 78, 1768-1778.	1.2	19
44	Three-Year Outcomes of Orbital Atherectomy for the Endovascular Treatment of Infrainguinal Claudication or Chronic Limb-Threatening Ischemia. Journal of Endovascular Therapy, 2020, 27, 714-725.	0.8	17
45	Assessing health-related quality of life among patients with peripheral artery disease: A review of the literature and focus on patient-reported outcome measures. Vascular Medicine, 2021, 26, 317-325.	0.8	17
46	North American lower-extremity revascularization and amputation during COVID-19: Observations from the Vascular Quality Initiative. Vascular Medicine, 2021, 26, 613-623.	0.8	17
47	Sex differences in presentation, management, and outcomes among patients hospitalized with acute pulmonary embolism. Vascular Medicine, 2020, 25, 541-548.	0.8	16
48	Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel 0ated Devices: Insights From the Veterans Health Administration. Journal of the American Heart Association, 2021, 10, e018149.	1.6	16
49	Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non–ST-Segment–Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	15
50	Readmissions after acute type B aortic dissection. Journal of Vascular Surgery, 2020, 72, 73-83.e2.	0.6	15
51	Use, Safety and Effectiveness of Subintimal Angioplasty and Re-Entry Devices for the Treatment of Femoropopliteal Chronic Total Occlusions: A Systematic Review of 87 Studies and 4,665 Patients. Cardiovascular Revascularization Medicine, 2020, 21, 34-45.	0.3	14
52	Trends in utilization and spending on remote monitoring of pacemakers and implantable cardioverter–defibrillators among Medicare beneficiaries. Heart Rhythm, 2020, 17, 1917-1921.	0.3	14
53	Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006275.	0.9	14
54	Three-Year Outcomes From the LIBERTY 360 Study of Endovascular Interventions for Peripheral Artery Disease Stratified by Rutherford Category. Journal of Endovascular Therapy, 2021, 28, 262-274.	0.8	14

#	Article	IF	CITATIONS
55	Correlating the Dermatology Life Quality Index and Skin Discoloration Impact Evaluation Questionnaire tools in disorders of hyperpigmentation. Journal of Dermatology, 2018, 45, 361-362.	0.6	13
56	Association of Socioeconomic Disadvantage With Mortality and Readmissions Among Older Adults Hospitalized for Pulmonary Embolism in the United States. Journal of the American Heart Association, 2021, 10, e021117.	1.6	13
57	Acute Pulmonary Embolism During Pregnancy and Puerperium. Mayo Clinic Proceedings, 2021, 96, 2102-2113.	1.4	13
58	Outcomes in Patients Undergoing PrimaryÂPercutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin VersusÂHeparin. JACC: Cardiovascular Interventions, 2017, 10, 1102-1111.	1.1	12
59	The Most Beautiful People. JAMA Dermatology, 2017, 153, 1327.	2.0	12
60	Long-term safety of drug-coated devices for peripheral revascularisation. EuroIntervention, 2021, 17, 590-598.	1.4	12
61	Intravascular ultrasound guidance for lower extremity arterial and venous interventions. EuroIntervention, 2022, 18, 598-608.	1.4	12
62	Acute Kidney Injury Following In-Patient Lower Extremity Vascular Intervention. JACC: Cardiovascular Interventions, 2021, 14, 333-341.	1.1	11
63	Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry. American Heart Journal, 2019, 216, 74-81.	1.2	10
64	Trends in Use of Prescription Skin Lightening Creams. International Journal of Environmental Research and Public Health, 2021, 18, 5650.	1.2	10
65	Intravascular ultrasound in peripheral venous and arterial interventions: A contemporary systematic review and grading of the quality of evidence. Vascular Medicine, 2022, 27, 392-400.	0.8	10
66	Temporal Changes and Institutional Variation in Use of Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction With Multivessel Coronary Artery Disease in the United States. JAMA Cardiology, 2021, 6, 574.	3.0	9
67	Clinical Impact of Contralateral Carotid Occlusion in Patients Undergoing Carotid Artery Revascularization. Journal of the American College of Cardiology, 2021, 77, 835-844.	1.2	9
68	Usefulness of a Computerized Reminder System to Improve Inferior Vena Cava Filter Retrieval and Complications. American Journal of Cardiology, 2019, 123, 348-353.	0.7	8
69	Appearanceâ€based vs healthâ€based sun protective messages: A randomized, doubleâ€blind controlled study. Journal of Cosmetic Dermatology, 2019, 18, 1030-1036.	0.8	8
70	Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.	1.6	8
71	Risk Stratification and Management of Extracranial Carotid Artery Disease. Cardiology Clinics, 2021, 39, 539-549.	0.9	8
72	Lead-Related Venous Obstruction in Patients With Implanted Cardiac Devices. Journal of the American College of Cardiology, 2022, 79, 299-308.	1.2	8

#	Article	IF	CITATIONS
73	Outcomes Associated With Peripheral Artery Disease in Myocardial Infarction With Cardiogenic Shock. Journal of the American College of Cardiology, 2022, 79, 1223-1235.	1.2	8
74	Association of Frailty With Treatment Selection and Longâ€Term Outcomes Among Patients With Chronic Limbâ€Threatening Ischemia. Journal of the American Heart Association, 2021, 10, e023138.	1.6	8
75	Target Vessel Revascularization and Territory of Myocardial Ischemia in Patients With Chronic Total Occlusions. Journal of the American College of Cardiology, 2017, 70, 1196-1197.	1.2	7
76	Inferior Vena Cava Filters and Mortality. JAMA Network Open, 2018, 1, e180453.	2.8	7
77	Paclitaxel-Based Devices for the Treatment of PAD: Balancing Clinical Efficacy with Possible Risk. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 57.	0.4	7
78	Active smoking is associated with higher rates of incomplete wound healing after endovascular treatment of critical limb ischemia. Vascular Medicine, 2020, 25, 427-435.	0.8	7
79	Rationale and Design of the SAFE-PAD Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007040.	0.9	7
80	Interhospital Transfer for the Management of Acute Pulmonary Embolism. American Journal of Medicine, 2022, 135, 531-535.	0.6	7
81	Seasonality and Readmission after Heart Failure, Myocardial Infarction, and Pneumonia. Health Services Research, 2018, 53, 2185-2202.	1.0	6
82	Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 273-279.	1.8	6
83	Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 569-578.	0.7	6
84	One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS121011506.	1.4	6
85	Understudied factors in drugâ€coated balloon design and evaluation: A biophysical perspective. Bioengineering and Translational Medicine, 2023, 8, .	3.9	6
86	Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLoS ONE, 2018, 13, e0205457.	1.1	5
87	New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries) Tj ETQq1 1 C	.784 <u>314</u> rgl 0.7	BT /Overlock
88	Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPEN TO Registry. Journal of the American Heart Association, 2022, 11, e024056.	1.6	5
89	Update From the Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS122012074.	1.4	5
90	Clinical Features of Heart Failure and Acute Coronary Syndromes. Clinics in Laboratory Medicine, 2014, 34, 15-30.	0.7	4

#	Article	IF	CITATIONS
91	Mitral Annular and Coronary Artery Calcification Are Associated with Mortality in HIV-Infected Individuals. PLoS ONE, 2015, 10, e0130592.	1.1	4
92	Complete vs Incomplete Revascularization During Percutaneous Coronary Intervention and Improved Survival—The Key Is Immortality. JAMA Cardiology, 2018, 3, 443.	3.0	4
93	Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. American Heart Journal, 2021, 233, 59-67.	1.2	4
94	Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360° trial. Journal of Medical Economics, 2021, 24, 570-580.	1.0	4
95	The Safety of Paclitaxel-Coated Devices for Patients with Peripheral Artery Disease. Current Cardiology Reports, 2021, 23, 48.	1.3	4
96	Sex Disparities in Long-Term Mortality after Paclitaxel Exposure in Patients with Peripheral Artery Disease: A Nationwide Claims-Based Cohort Study. Journal of Clinical Medicine, 2021, 10, 2978.	1.0	4
97	Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction Among Medicare Beneficiaries With Multivessel Coronary Artery Disease: An National Cardiovascular Data Registry Research to Practice Project. Circulation: Cardiovascular Interventions. 2021. 14. e010323.	1.4	4
98	Development and validation of a predictive model for bleeding after peripheral vascular intervention: A report from the National Cardiovascular Data Registry Peripheral Vascular Interventions Registry. Catheterization and Cardiovascular Interventions, 2021, 98, 1363-1372.	0.7	4
99	Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI). Vascular Medicine, 2022, 27, 73-74.	0.8	4
100	Effect of stimuli on sun protective habits: A randomized doubleâ€blind controlled study. Photodermatology Photoimmunology and Photomedicine, 2019, 35, 17-23.	0.7	3
101	The impact of chronic kidney disease on outcomes following peripheral vascular intervention. Clinical Cardiology, 2020, 43, 1308-1316.	0.7	3
102	Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank. Catheterization and Cardiovascular Interventions, 2021, 98, 904-913.	0.7	3
103	Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice. JACC: Cardiovascular Interventions, 2021, 14, 2112-2123.	1.1	3
104	Accuracy of Administrative Claims Codes for Identifying Devices Used in Endovascular Femoropopliteal Artery Revascularisation: A Retrospective Observational Study at Two Tertiary Centres in the United States. European Journal of Vascular and Endovascular Surgery, 2022, 63, 769-770.	0.8	3
105	Atherectomy vs Other Modalities for Treatment During Peripheral Vascular Intervention. Current Cardiology Reports, 2022, 24, 869-877.	1.3	3
106	Response to Letter Regarding Article, "Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention― Circulation, 2015, 132, e156.	1.6	2
107	Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician. Progress in Cardiovascular Diseases, 2018, 60, 491-499.	1.6	2
108	Re: Multivessel Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction with Cardiogenic Shock. Epidemiology, 2018, 29, e59-e60.	1.2	2

#	Article	IF	CITATIONS
109	Exposure Misclassification in Observational Studies. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004939.	0.9	2
110	Acute pulmonary embolism following recent hospitalization or surgery. Journal of Thrombosis and Thrombolysis, 2021, 52, 189-199.	1.0	2
111	Intravascular Imaging for Venous Interventions. Current Cardiovascular Imaging Reports, 2020, 13, 1.	0.4	2
112	Vascular Access and Closure for Peripheral Arterial Intervention. Interventional Cardiology Clinics, 2020, 9, 117-124.	0.2	2
113	Treatment decisions for patients with peripheral artery disease and symptoms of claudication: Development process and alpha testing of the SHOW-ME PAD decision aid. Vascular Medicine, 2021, 26, 273-280.	0.8	2
114	Femoral-popliteal peripheral artery disease: From symptom presentation to management and treatment controversies. Progress in Cardiovascular Diseases, 2021, 65, 15-22.	1.6	2
115	EFFECT OF TOCILIZUMAB ON CARDIAC INJURY AND DYSFUNCTION IN COVID-19. Journal of the American College of Cardiology, 2021, 77, 3028.	1.2	2
116	Illuminating the Path for Novel Peripheral Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2022, 15, 627-629.	1.1	2
117	Letter by Secemsky et al Regarding Article, "Relationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271 845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011: A Propensity Score–Corrected Analysis From the British Cardiovascular Intervention Societvâ€e Circulation: Cardiovascular Interventions. 2016. 9	1.4	1
118	Background and Room Illumination in Color Identification of Skin Lesions. JAMA Dermatology, 2017, 153, 1059.	2.0	1
119	Brachial-ankle pulse wave velocity as a marker of adverse events following non-ST-elevation myocardial infarction. Coronary Artery Disease, 2017, 28, 634-635.	0.3	1
120	Triple Therapy: When, if Ever?. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 61.	0.4	1
121	Prognosis of Claims―Versus Trialâ€Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. Journal of the American Heart Association, 2021, 10, e018744.	1.6	1
122	Ordering from the bill instead of from the menu. Catheterization and Cardiovascular Interventions, 2021, 98, 1141-1143.	0.7	1
123	Venous Thromboembolism for the Practicing Cardiologist. Cardiology Clinics, 2021, 39, 551-566.	0.9	1
124	Comparative Effectiveness of Reperfusion Strategies in Patients with ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the Acute Coronary Syndrome Quality Improvement in Kerala (ACS) Tj ETQq(	) 0 <b>0.</b> æBT	/Overlock 10
125	Response Team Management of Acute Serious Pulmonary Embolism. Texas Heart Institute Journal, 2021, 48, .	0.1	1

<sup>126</sup>Part II: Cutaneous manifestations of peripheral vascular disease. Journal of the American Academy of<br/>Dermatology, 2023, 89, 211-226.0.61

#	Article	IF	CITATIONS
127	Entering a Polymer-Free Era. Circulation: Cardiovascular Interventions, 2019, 12, e007676.	1.4	0
128	Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coronary Artery Disease, 2019, 30, 177-182.	0.3	0
129	Shedding Some â€~Light' on Below-the-Knee Intervention in CLI With Lasers. Cardiovascular Revascularization Medicine, 2021, 23, 84-85.	0.3	0
130	Turning the tide: Evolution of below-the-knee endovascular intervention. Vascular Medicine, 2021, 26, 26-27.	0.8	0
131	Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis. Journal of Endovascular Therapy, 2021, 28, 246-254.	0.8	0
132	Contemporary Use of Radial to Peripheral Access for Management of Peripheral Artery Disease. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	0
133	National trends in utilization of thrombolytic therapy for acute pulmonary embolism. Vascular Medicine, 2021, , 1358863X2110485.	0.8	0
134	Seeing the entire elephant: The challenges of frailty assessment for peripheral artery disease. Vascular Medicine, 2022, , 1358863X2210888.	0.8	0
135	Part I: Cutaneous manifestations of cardiovascular disease. Journal of the American Academy of Dermatology, 2023, 89, 197-208.	0.6	0
136	Disrupting the Management of Calcified Femoropopliteal Peripheral Artery Disease: Mid-term Outcomes From Disrupt PAD III. , 2022, , 100369.		0